ArticleFrontiers in microbiology2026
Analysis of imported Chikungunya cases in China from 2006 to 2026.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chikungunya fever (CHIKF) has impacted 119 countries and regions globally. In 2025, a local outbreak occurred in Guangdong, China, driven by imported cases from Sri Lanka, resulting in over 25,000 diagnoses. This highlights CHIKF as a significant public health concern. Analyzing imported cases in China and discussing travel medicine and related preventive measures is essential. Methods: This study reviewed literature and reports on CHIKF published in international and Chinese databases, as well as government reports, from 2006 to March 1, 2026. Data related to CHIKF, including case numbers, virus types, source countries, and high-risk provinces, were collected, synthesized, and summarized using descriptive statistical methods. Phylogenetic tree analysis, temporal signal assessment, and mutation analysis were conducted on the Chikungunya virus (CHIKV) sequences sourced from China. Results: Between 2006 and 2026, China reported a total of 259 imported CHIKF cases, including those from Hong Kong, Macao, and Taiwan. These imported cases contributed to over 25,000 local transmission cases. Among confirmed cases, the East/Central/South African (ECSA) strain was the most prevalent (61.7%), followed by the Asian strain (37.4%). The primary countries of acquisition were Indonesia and Myanmar, with the Asian strain mostly detected in travelers returning from Indonesia, while the ECSA strain was found in travelers from South and Southeast Asia. The rate of evolution for Chinese cases mirrors that of global trends, and no new branches have emerged. The newly identified mutations in recent years exhibit high-frequency variations in the sequences, along with potential unidentified mutations that have appeared. Conclusion: Returnees from countries with high incidence rates of CHIKF significantly increase the risk of reintroducing the disease to China. An increased number of mutations may enhance the transmission of CHIKV. Therefore, it is crucial to enhance the dissemination of relevant prevention and control measures and expedite vaccine approval to mitigate the incidence of CHIKF among travelers and reduce viral transmission.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.